Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Statkevich

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced MalignanciesJason Zhang, Kinjal Sanghavi, Jun Shen, et al.
European Journal of Clinical Pharmacology|December 2, 2010
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjectsTeddy Kosoglou, Yali Zhu, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of DigoxinTeddy Kosoglou, Yali Zhu, Paul Statkevich, et al.
European Journal of Clinical Pharmacology|April 6, 2012
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarinTeddy Kosoglou, Yali Zhu, Fengjuan Xuan, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic interaction between ezetimibe and rosuvastatinTeddy Kosoglou, Paul Statkevich, Bo Yang, et al.
Journal of Clinical Pharmacology|February 22, 2013
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxarTeddy Kosoglou, Paul Statkevich, Bharath Kumar, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazoneTeddy Kosoglou, Bharath Kumar, Paul Statkevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid TumorsYue Zhao, Zheyi Hu, Sai Praneeth Bathena, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult SubjectsMartin O Behm, Teddy Kosoglou, André M M Miltenburg, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced MalignanciesJason Zhang, Kinjal Sanghavi, Jun Shen, et al.
European Journal of Clinical Pharmacology|December 2, 2010
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjectsTeddy Kosoglou, Yali Zhu, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of DigoxinTeddy Kosoglou, Yali Zhu, Paul Statkevich, et al.
European Journal of Clinical Pharmacology|April 6, 2012
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarinTeddy Kosoglou, Yali Zhu, Fengjuan Xuan, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic interaction between ezetimibe and rosuvastatinTeddy Kosoglou, Paul Statkevich, Bo Yang, et al.
Journal of Clinical Pharmacology|February 22, 2013
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxarTeddy Kosoglou, Paul Statkevich, Bharath Kumar, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazoneTeddy Kosoglou, Bharath Kumar, Paul Statkevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid TumorsYue Zhao, Zheyi Hu, Sai Praneeth Bathena, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult SubjectsMartin O Behm, Teddy Kosoglou, André M M Miltenburg, et al.
Pageof 5